Previous 10 | Next 10 |
2023-08-16 03:00:21 ET Summary Baupost Group's 13F portfolio value decreased from $5.85B to $5.61B this quarter. The portfolio is heavily concentrated, with Liberty Global, Liberty Media Sirius XM, ViaSat, Alphabet, and Veritiv accounting for approximately 58% of the holdings. ...
2023-08-07 21:33:13 ET Theravance Biopharma, Inc. (TBPH) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Rick Graham - Head of Research and Developmen...
2023-08-07 16:15:14 ET Theravance Biopharma press release ( NASDAQ: TBPH ): Q2 GAAP EPS of -$0.28 misses by $0.07 . Revenue of $13.75M (+23.9% Y/Y) misses by $1.67M . Cash Position: Cash, cash equivalents and marketable securities totaled $167.5 million as of J...
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Q2 2023 YUPELRI ® (revefenacin) net sales of $55.0 million , recognized by Viatris, up 12% from Q2 2022 1 Q2 2023 YUPELRI total reta...
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023 PR Newswire DUBLIN , July 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business u...
2023-06-22 12:14:19 ET The major market averages trade significantly higher on the year as investors approach the halfway point of 2023. However, not every stock finds itself on easy street with some market participants shorting popular names. As a frame of reference, short interest ref...
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy PR Newswire DUBLIN , May 9, 2023 /PRNewswire/ -- Theravance Biopharm...
2023-05-08 22:39:05 ET Theravance Biopharma, Inc. (TBPH) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Rick Graham – Senior Vice P...
2023-05-08 16:25:56 ET Theravance Biopharma press release ( NASDAQ: TBPH ): Q1 GAAP EPS of -$0.35 misses by $0.10 . Revenue of $10.4M (-21.2% Y/Y) misses by $3.3M . On track to complete $325 million capital return program by year-end. TBPH reaffirms its exp...
Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire Q1 2023 YUPELRI ® (revefenacin) net sales of $47.0 million , recognized by Viatris, up 8% from Q1 2022 1 Q1 2023 YUPELRI retail new p...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...